These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22684241)

  • 1. A statistical approach to central monitoring of data quality in clinical trials.
    Venet D; Doffagne E; Burzykowski T; Beckers F; Tellier Y; Genevois-Marlin E; Becker U; Bee V; Wilson V; Legrand C; Buyse M
    Clin Trials; 2012 Dec; 9(6):705-13. PubMed ID: 22684241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central statistical monitoring: detecting fraud in clinical trials.
    Pogue JM; Devereaux PJ; Thorlund K; Yusuf S
    Clin Trials; 2013 Apr; 10(2):225-35. PubMed ID: 23283577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
    Brosteanu O; Houben P; Ihrig K; Ohmann C; Paulus U; Pfistner B; Schwarz G; Strenge-Hesse A; Zettelmeyer U
    Clin Trials; 2009 Dec; 6(6):585-96. PubMed ID: 19897532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Public clinical trials: which kind of monitoring should be used?].
    Cornu C; Binquet C; Thalamas C; Vigouroux C; Gaillard S; Ginhoux T; Vaz B; Jossan C; Félin A; Sailly A; Gueyffier F; Journot V; Kassaï B
    Therapie; 2013; 68(3):135-41. PubMed ID: 23886457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring.
    Trotta L; Kabeya Y; Buyse M; Doffagne E; Venet D; Desmet L; Burzykowski T; Tsuburaya A; Yoshida K; Miyashita Y; Morita S; Sakamoto J; Praveen P; Oba K
    Clin Trials; 2019 Oct; 16(5):512-522. PubMed ID: 31331195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic search for reports of site monitoring technique comparisons in clinical trials.
    Bakobaki J; Joffe N; Burdett S; Tierney J; Meredith S; Stenning S
    Clin Trials; 2012 Dec; 9(6):777-80. PubMed ID: 23059772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of methods for central statistical monitoring in clinical trials.
    Kirkwood AA; Cox T; Hackshaw A
    Clin Trials; 2013 Oct; 10(5):783-806. PubMed ID: 24130202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A web-based clinical trial management system for a sham-controlled multicenter clinical trial in depression.
    Durkalski V; Wenle Zhao ; Dillon C; Kim J
    Clin Trials; 2010 Apr; 7(2):174-82. PubMed ID: 20083496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial.
    Timmermans C; Doffagne E; Venet D; Desmet L; Legrand C; Burzykowski T; Buyse M
    Gastric Cancer; 2016 Jan; 19(1):24-30. PubMed ID: 26298185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linear mixed-effects models for central statistical monitoring of multicenter clinical trials.
    Desmet L; Venet D; Doffagne E; Timmermans C; Burzykowski T; Legrand C; Buyse M
    Stat Med; 2014 Dec; 33(30):5265-79. PubMed ID: 25213096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panel discussion 2.
    Lan G; Lindborg S; Neaton J
    Clin Trials; 2012 Dec; 9(6):736-40. PubMed ID: 23250944
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.
    Brosteanu O; Schwarz G; Houben P; Paulus U; Strenge-Hesse A; Zettelmeyer U; Schneider A; Hasenclever D
    Clin Trials; 2017 Dec; 14(6):584-596. PubMed ID: 28786330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific barriers to the conduct of randomized trials.
    Duley L; Antman K; Arena J; Avezum A; Blumenthal M; Bosch J; Chrolavicius S; Li T; Ounpuu S; Perez AC; Sleight P; Svard R; Temple R; Tsouderous Y; Yunis C; Yusuf S
    Clin Trials; 2008; 5(1):40-8. PubMed ID: 18283079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
    Paciorek CJ; Liu Y;
    Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trial Educator program - a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial.
    Kendall B; Städeli R; Schegg B; Olbrich M; Chen E; Harmelin-Kadouri R; Aurup P; Schwab T; Hildemann SK
    Clin Trials; 2012 Jun; 9(3):358-66. PubMed ID: 22426648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical considerations in industry-sponsored multiregional clinical trials.
    Ibia E; Binkowitz B; Saillot JL; Talerico S; Koerner C; Ferreira I; Agarwal A; Metz C; Maman M
    Pharm Stat; 2010; 9(3):230-41. PubMed ID: 20824884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.